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Randomized Comparison of Eptifibatide
Versus Abciximab in Primary Percutaneous
Coronary Intervention in Patients With Acute
ST-Segment Elevation Myocardial Infarction
Results of the EVA-AMI Trial
Uwe Zeymer, MD,*† Alain Margenet, MD,‡ Michael Haude, MD,§ Christoph Bode, MD,
Jean-Marc Lablanche, MD,¶ Hubertus Heuer, MD,# Rolf Schröder, MD,** Stefan Kropff, MD,††
Ryad Bourkaib, MD,†† Norbert Banik, PHD,†† Ralf Zahn, MD,* Emmanuel Teiger, MD, PHD‡
Ludwigshafen, Neuss, Freiburg, Dortmund, and Berlin, Germany; Creteil and Lille, France;
and London, United Kingdom
Objectives The aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary
intervention (PCI).
Background The glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST-segment
elevation myocardial infarctions has been shown to reduce ischemic complications and improve clinical out-
comes. So far, no trial has been performed to compare the efficacy of another GP IIb/IIIa receptor inhibitor,
eptifibatide, and abciximab in primary PCI.
Methods A total of 427 patients with ST-segment elevation myocardial infarctions 12 h and planned primary PCI were
randomized to double-bolus eptifibatide (n  226) followed by a 24-h infusion or single-bolus abciximab (n 
201) followed by a 12-h infusion. In this noninferiority trial, the primary end point was the incidence of complete
(70%) ST-segment resolution (STR) 60 min after PCI, a measure of myocardial reperfusion. The assumption
was a 60% complete STR rate in the abciximab group. The noninferiority margin was set to 15%.
Results The incidence of complete STR at 60 min after PCI in the intention-to-treat analysis was 62.6% after eptifibatide
and 56.3% after abciximab (adjusted difference: 7.1%; 95% confidence interval: 2.7% to 17.0%). All-cause mor-
tality 6.2% versus 4.5% (p  0.50); reinfarction 0.4% versus 3.5% (p  0.03); target vessel revascularization
4.4% versus 6.5% (p  0.40); the combined end point of death, nonfatal reinfarction, and target vessel revascu-
larization 10.6% versus 10.9% (p  0.90); stroke 0.5% versus 0.5% (p  1.00) after 6 months; and Thromboly-
sis In Myocardial Infarction major bleeding complications 4.0% versus 2.0% (p  0.20) after 30 days were ob-
served after eptifibatide and abciximab, respectively.
Conclusions Eptifibatide as an adjunct to primary PCI is equally as effective as abciximab with respect to STR. (Efficacy of
Eptifibatide Compared to Abciximab in Primary Percutaneous Coronary Intervention [PCI] for Acute ST Elevation
Myocardial Infarction [STEMI]; NCT00426751) (J Am Coll Cardiol 2010;56:463–9) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.093(
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Eptifibatide Versus Abciximab in Primary PCI August 3, 2010:463–9well recognized as major prob-
lems in primary PCI (4,5). In
several randomized trials and a
recent meta-analysis, abciximab
plus heparin have been shown to
improve the clinical courses of
patients with primary PCI by
improving myocardial reperfu-
sion, left ventricular function,
and clinical outcomes compared
with heparin alone (3,6 –9).
These studies have been mainly
performed without the upstream
administration of thienopyri-
dines. Therefore, the current
PCI guidelines of the European
ociety of Cardiology recommend abciximab in primary
CI (Class IIa, Level of Evidence: A) (10). The recently
See page 476
ublished ON-TIME2 (Ongoing Tirofiban in Myocardial
nfarction Evaluation 2) trial showed that high-bolus dose
irofiban improved myocardial reperfusion and clinical out-
omes after primary PCI compared with placebo with
rovisional tirofiban in 29% during PCI (11). This positive
esult supports the use of glycoprotein (GP) IIb/IIIa inhib-
tors, in addition to a loading dose of clopidogrel, for
atients with STEMI. Abciximab and eptifibatide reduced
he rate of thrombotic complications in patients with
onurgent stent implantation (12,13). Eptifibatide, a syn-
hetic specific GP IIb/IIIa inhibitor, is less expensive than
bciximab and induces a reversible receptor occupation.
latelet function is normalized 4 to 6 h after termination of
nfusion, which is desirable in patients with unplanned
rgent coronary bypass grafting (14). In 2 randomized trials,
ptifibatide was associated with an improvement in Throm-
olysis In Myocardial Infarction (TIMI) flow grade 3
atency before primary PCI (15,16). This advantage was in
he same magnitude as observed in trials using abciximab
17,18). According to a recent report, eptifibatide is the
ost commonly used GP IIb/IIIa inhibitor in primary PCI
n the U.S. (19). Therefore, we sought to compare the
fficacy and safety of eptifibatide and abciximab in primary
CI in adjunction to the standard pharmacological treat-
ent including clopidogrel.
ethods
tudy design and patients. The EVA-AMI (Eptifibatide
ersus Abciximab in Primary PCI for Acute Myocardial
nfarction) trial was an international, multicenter, random-
zed, prospective, open parallel group comparison of eptifi-
atide, clopidogrel, acetylsalicylic acid (ASA), and heparin
Abbreviations
and Acronyms
ASA  acetylsalicylic acid
ECG  electrocardiogram
GP  glycoprotein
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
STR  ST-segment
resolution
TIMI  Thrombolysis In
Myocardial Infarctionr enoxaparin versus abciximab, clopidogrel, ASA, and veparin or enoxaparin in patients with STEMI 12 h
ndergoing primary PCI.
The primary objective of the trial was to demonstrate the
oninferiority of eptifibatide compared with abciximab as an
djunct in patients undergoing primary PCI for STEMI.
The study population consisted of patients age 18 years
ith STEMI 12 h and planned primary PCI. They
ere eligible for randomization if they had experienced
ngina or equivalent symptoms of more than 20 min and
T-segment elevation in 2 contiguous leads (2 mm
recordial lead, 1 mm limb lead) and had given written
nformed dated consent to participate in the study. Exclu-
ion criteria were the following: left bundle branch block,
hrombolytic therapy within 24 h before randomization,
ral anticoagulation with international normalized ratio2,
nown platelets 100,000/l or known hemorrhagic dia-
hesis, stroke or transient ischemic attack within 30 days in
he past 6 months or any permanent residual neurological
efect, evidence of an active gastrointestinal or urogenital
leeding, major surgery within 6 weeks, history of allergic
eaction to abciximab or eptifibatide or any component used
n the study (including contrast media), known severe renal
creatinine clearance 30 ml/min) or hepatic insufficiency,
evere concomitant disease with life expectancy 1 year,
articipation in any study using an investigational drug or
evice within 30 days or within 5 half-lives of the investi-
ational drug (whichever was longer) of entry into this
tudy, and inaccessibility due to geographic or social factors
uring treatment or follow-up.
The study was approved by all local ethics committees
nvolved. Randomization was stratified by infarct location
anterior vs. nonanterior) and done using sealed and opaque
nvelopes.
rocedures. Patients randomized to eptifibatide received a
ouble bolus of 180 g/kg (10-min interval) followed by an
nfusion of 2.0 g/kg/min over 24 h as early as possible.
atients randomized to abciximab received a bolus of 0.25
g/kg followed by an infusion of 0.125 g/kg/min over
2 h.
Angiographic catheter evaluation of the anatomy of the
oronary arteries and PCI, possibly with stent implantation,
ere done according to the local guidelines as early as
ossible but at least within 2 h after randomization. PCI
nd stenting if feasible of the infarct-related coronary artery
ere performed. The use of thrombectomy devices and the
ntracoronary use of medications such as adenosine, vera-
amil, or other calcium-channel blockers were left to the
iscretion of the investigator. In case of multivessel disease,
CI of the nonculprit lesions should be postponed if
ossible for at least 1 week.
nd points. The primary end point was the incidence of
uccessful myocardial reperfusion as measured by complete
T-segment resolution (STR) (70%) 60 min (range 45 to
5 min) after PCI as assessed by a blinded core electro-
ardiographic (ECG) laboratory (20,21). ST-segment ele-
ation was analyzed by a single investigator (R.S.) with
l
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August 3, 2010:463–9 Eptifibatide Versus Abciximab in Primary PCIens-intensified calipers to the nearest 0.025 mV 20 ms after
he end of the QRS complex, with the PR segment as the
eference baseline, from leads I, aVL, and V1 to V6 for
nterior infarction and leads II, III, aVF, V5, and V6 for
nferior infarction. ST-segment depression from leads with
0.1-mV depression were measured in leads II, III, and
VF for anterior and leads V1 to V4 for inferior infarction.
um STR was measured by the sum of ST-segment
levation from all ECG leads related to infarct location.
ingle-lead STR was measured by the ST-segment devia-
ion on the single lead that showed maximum deviation at
aseline and at 60 min, irrespective of the ECG lead in
hich ST-segment deviation was measured at baseline.
TR was expressed as percent from baseline and graded as
omplete (70%), partial (70% to 30%), or none (30%).
lectrocardiograms were obtained before randomization,
irectly before angiography, and 60 min after the comple-
ion of PCI.
Secondary end points included other ECG measures of
yocardial reperfusion and angiographic assessments of the
atency of the infarct-related artery (TIMI flow grade 3 and
IMI flow grade 2/3 patency before the procedure, TIMI
ow grade 3 patency after the procedure as assessed by a
ore angiographic laboratory [22], corrected TIMI frame
ount, and myocardial blush grade before and after PCI). In
ddition, individual and combined clinical end points of
eath, reinfarction, urgent target vessel revascularization,
troke, and bleeding complications as assessed by the TIMI
cale (22) until day 30 were reported. Clinical follow-up was
one until 6 months, looking for the occurrence of death,
einfarction, and urgent target vessel revascularization. A
linded clinical end point committee adjudicated all clinical
nd points.
atient populations. The safety population comprised all
ubjects who received at least 1 dose of study medication.
he intention-to-treat population comprised all random-
zed subjects who received at least 1 dose of study medica-
ion and fulfilled the ECG inclusion criteria.
tatistical analysis. The null hypothesis tested was that
ptifibatide is inferior to abciximab in terms of the rate of
omplete STR 60 min after PCI. The alternative hypothesis
as the noninferiority of eptifibatide compared with abcix-
mab in this primary efficacy end point. This hypothesis was
ested via the lower limit of the 1-sided 95% confidence
nterval of the difference of the STR rate if under eptifi-
atide minus the one under abciximab. The a priori assump-
ion was that both treatments were able to demonstrate a
0% rate of complete STR within 60 min after PCI. The
oninferiority margin was set to 15%. Under these assump-
ions, the study would have needed 181 patients per group
vailable for the primary efficacy analysis to guarantee 90%
ower. Assuming a rate of 10% of unevaluable patients for
he per protocol analysis, it was planned to randomize
pproximately 400 subjects to achieve at least 352 (176 per
roup) evaluable subjects. cA generalized model (under binomial probability distri-
ution) stratified and adjusted by center was used to assess
reatment differences in the primary efficacy end point
complete sum STR). Results are presented in the form of
ifferences of the response rates between the treatment
roups with the associated lower limit of the 1-sided 95%
onfidence interval. The latter statistical estimate was used
or the decision on the inferiority null hypothesis. Analyses
f clinical outcomes and bleeding were based on the safety
opulation. Descriptive statistics were generated for baseline
nd clinical demographics, treatment variables, and out-
omes. The continuous variables were assessed using the
ilcoxon rank sum test, and values are presented as
edians and quartiles. Comparisons between the groups
ere done using Fisher exact tests. A p value 0.05 was
onsidered significant. The analysis was performed using
AS version 8.2 (SAS Institute Inc., Cary, North Carolina).
esults
etween November 2006 and May 2007, a total of 427
atients (226 randomized to eptifibatide and 201 to abciximab)
ere enrolled at 22 centers (11 in France and 11 in Germany).
he randomization and the initiation of study medication were
one before angiography in 75%, during angiography in 21%
nd after angiography in 4% of the patients.
The 2 groups were well balanced with respect to baseline
ariables (Table 1). The time between the onset of symptoms
nd study medication was 3.9 3.2 h in the eptifibatide group
nd 3.8 3.8 h in the abciximab group. The interval between
nitial electrocardiography and the administration of study
rug was 54 38 min in the eptifibatide and 57 48 min in
he abciximab group. The time interval between the start of
tudy drug and angiography was 28  33 min in the eptifi-
atide group and 30  32 min in the abciximab group.
aseline Variables of the PatientsTable 1 Baseline Variables of the Patients
Variable
Eptifibatide
(n  226)
Abciximab
(n  201) p Value
Age (yrs) 61.3 12.4 60.5 12.7 0.49
Women 54 (23.9%) 40 (19.9%) 0.35
Current smokers 101 (44.7%) 96 (47.8%) 0.56
Diabetes 33 (14.6%) 35 (17.4%) 0.43
Hypertension 117 (51.8%) 95 (47.3%) 0.38
Hypercholesterolemia 91 (40.3%) 89 (44.3%) 0.43
Family history of MI 70 (31.0%) 60 (29.9%) 0.83
Previous MI 19 (8.4%) 17 (8.5%) 1.00
Previous PCI 16 (7.1%) 17 (8.5%) 0.72
Previous CABG 7 (3.1%) 2 (1.0%) 0.18
Killip class 1 22 (9.8%) 20 (10.0%) 1.00
Heart rate (beats/min) 77.3 17.7 77.2 17.6 0.96
Systolic blood pressure (mm Hg) 136.0 24.7 135.8 20.9 0.94
Diastolic blood pressure (mm Hg) 80.2 15.4 80.6 13.9 0.80
Time between symptom onset and
start of study medication (min)
234.1 177.6 221.3 203.1 0.58
ata are expressed as mean  SD or as n (%).
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneous
oronary intervention.
C
a
p
g
p
d
a
m
a
i
(
r
a
o
u
t
t
6
g
T
p
6
d
a
m
P
w
m
a
v
n
g
6
A
D
a
M
C
A
a
Si
466 Zeymer et al. JACC Vol. 56, No. 6, 2010
Eptifibatide Versus Abciximab in Primary PCI August 3, 2010:463–9oronary angiography was performed and available for central
nalysis in 424 patients. The angiographic results and PCI
rocedures are shown in Table 2 and did not differ between the
roups. Radial access was used in 27% versus 30% of the
atients with eptifibatide versus abciximab, respectively. Study
rug was infused for 22.6  54.8 h in the eptifibatide group
nd 14.0  5.1 h in the abciximab group. The concomitant
edication consisted of ASA, clopidogrel, heparin or enox-
parin, statins, beta-blockers, and renin-angiotensin system
nhibitors in a high percentage of patients in both groups
Table 3). Clopidogrel was initiated 30 min before angiog-
aphy in 52.0%, 30 to 1 min before angiography in 7%, and
fter angiography in 20%, and the timing was unknown in 21%
f the patients.
ngiographic and Procedural FindingsTable 2 Angiographic and Procedural Findings
Variable
Eptifibatide
(n  224)
Abciximab
(n  200) p Value
Infarct-related artery
RCA 100 (44.6%) 90 (45.2%) 1.00
RCX 20 (8.9%) 21 (10.6%) 0.62
LAD 98 (43.8%) 86 (43.2%) 0.92
Left main 0 1 (0.5%) 0.47
Graft 6 (2.7%) 1 (0.5%) 0.13
Findings before PCI
TIMI flow grade
Not determined 22 10
0/1 117 (57.9%) 123 (64.7%) 1.00
2 11 (5.5%) 8 (4.2%) 0.39
3 74 (36.6%) 59 (31.0)
Corrected TIMI frame count 44.5 41.4 43.7 32.2 0.89
Myocardial blush grade
Not determined 40 30
0/1 126 (68.5%) 138 (82.2%)
2 1 (0.5%) 0 0.01
3 57 (31.0%) 32 (18.8%)
PCI performed 215 (95.1%) 191 (95.0%) 1.00
Stent implanted 204 (94.9%) 181 (94.8%) 1.00
BMS 171 (83.8%) 145 (80.6%) 0.35
DES 30 (14.9%) 33 (18.4%) 0.41
Direct stenting 67.6% 59.3%
Thrombectomy 40 (18.6%) 32 (16.8%) 0.70
Urgent CABG 2 (0.9%) 3 (1.5%) 0.67
Elective CABG 5 (2.2%) 6 (3.0%) 0.76
Findings after PCI
TIMI flow grade
Not determined 38 28
0/1 10 (5.6%) 11 (6.7%)
2 22 (12.4%) 15 (9.2%) 0.60
3 145 (82.0%) 137 (84.0%)
Median corrected TIMI frame count 25.3 21.0 23.6 17.6 0.42
Myocardial blush grade
0/1 111 (52.1%) 107 (54.8%)
2 1 (0.5%) 0 0.65
3 64 (30.0%) 54 (27.7%)
ata are expressed as mean  SD or as n (%).
BMS bare-metal stent(s); DES drug-eluting stent(s); LAD left anterior descending coronary
rtery; RCA right coronary artery; RCX right circumflex coronary artery; TIMI Thrombolysis In
yocardial Infarction; other abbreviations as in Table 1.
DThe number of patients fulfilling the inclusion criteria
ndergoing PCI and with electrocardiograms available for
he central evaluation of STR was 381. In the intention-to-
reat analysis, the median time between PCI and the
0-min ECG study was 75  72 min in the eptifibatide
roup and 68  41 min in the abciximab group (p  0.60).
he incidence of complete STR in the intention-to-treat
opulation did not differ between the 2 groups and was
2.6% and 56.3% (adjusted difference: 7.1%; 95% confi-
ence interval: 2.7% to 17.0%) in the eptifibatide and
bciximab groups, respectively. The incidence of the pri-
ary end point of complete (70%) STR at 60 min after
CI in the per protocol analysis (including only patients
ith 60-min electrocardiograms in a window of 45 to 75
in after PCI) was 62.8% after eptifibatide and 58.6% after
bciximab (adjusted difference: 2.1%; 95% confidence inter-
al: 8.5% to 12.8%). Thus, the pre-specified margin for
oninferiority was met. Additional measures of STR are
iven in Table 4. The clinical events occurring during the
-months follow-up period are listed in Table 5 and
oncomitant MedicationTable 3 Concomitant Medication
Variable
Eptifibatide
(n  226)
Abciximab
(n  201) p Value
ASA 218 (96.5%) 189 (94.0%) 0.26
Clopidogrel 224 (99.2%) 197 (98.0%) 0.43
Unfractionated heparin 136 (60.2%) 129 (64.2%) 0.42
Low–molecular weight heparin 157 (69.5%) 143 (71.1%) 0.75
Beta-blocker 202 (89.4%) 181 (90.0%) 0.87
ACE inhibitor/ARB 184 (81.4%) 157 (78.1%) 0.40
Statins 205 (90.7%) 174 (86.6%) 0.22
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ASA  acetylsalicylic
cid.
T-Segment Deviation Analysisn th Intention-to-Treat-Analy isTable 4 ST-Segment Deviation Analysisin the Intention-to-Treat-Analysis
Variable
Eptifibatide
(n  198)
Abciximab
(n  183) p Value
Sum ST-segment deviation at
baseline (mm)
10.2 7.0 11.3 7.8 0.14
Findings before PCI
Sum STR (%) 25.9 32.0 21.2 29.0 0.21
Complete STR 19 (13.1%) 12 (10.0%) 0.34
Partial STR 30 (20.7%) 23 (19.2%) 0.31
No STR 96 (66.2%) 85 (70.8%) 0.32
Single-lead complete STR 12 (9.7%) 7 (6.3%) 0.75
Sum ST-segment deviation
before PCI (mm)
9.3 9.5 10.5 7.9 0.26
Findings 60 min after PCI
Sum STR (%) 71.6 27.2 66.3 31.1 0.08
Complete STR 124 (62.6%) 103 (56.3%) 0.16
Partial STR 56 (28.3%) 51 (27.9%) 0.99
No STR 18 (9.1%) 29 (15.8%) 0.04
Single-lead complete STR 105 (59.7%) 82 (49.1%) 0.06
Sum ST-segment deviation (mm) 2.9 3.6 3.9 4.4 0.01ata are expressed as mean  SD or as n (%).
PCI  percutaneous coronary intervention; STR  ST-segment resolution.
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August 3, 2010:463–9 Eptifibatide Versus Abciximab in Primary PCIevealed no significant differences between the 2 groups
Fig. 1), except for reinfarction, which occurred less often
fter eptifibatide (0.4% vs. 3.5%, p  0.03). Major bleeding
vents according to the TIMI classification were rare and
ccurred more often with eptifibatide, but this difference
as statistically not significant (Table 6).
iscussion
latelets play a major role in the pathogenesis of acute
oronary syndromes (4,5). Therefore, platelet inhibition is a
ornerstone of therapy in patients with STEMI (2). This is
umulative Clinical Outcomest Different Time PointsTable 5 Cumulative Clinical Outcomesat Different Time Points
Variable
Eptifibatide
(n  226)
Abciximab
(n  201) p Value
Until day 7 or discharge
Death/recurrent MI/TVR 12 (5.3%) 14 (7.0%) 0.55
Death 8 (3.5%) 7 (3.5%) 1.00
Recurrent MI 0 3 (1.5%) 0.10
TVR 5 (2.2%) 8 (4.0%) 0.40
Until day 30
Death/recurrent MI/TVR 17 (7.5%) 17 (8.5%) 0.72
Death 13 (5.8%) 7 (3.5%) 0.36
Recurrent MI 0 5 (2.5%) 0.02
TVR 5 (2.2%) 10 (5.0%) 0.19
Until 180 days
Death/recurrent MI/TVR 24 (10.6%) 23 (10.9%) 0.88
Death 14 (6.2%) 9 (4.5%) 0.52
Recurrent MI 1 (0.4%) 7 (3.5%) 0.03
TVR 10 (4.4%) 13 (6.5%) 0.39
I  myocardial infarction; TVR  target vessel revascularization.Figure 1 Cumulative Incidence of Death, Myocardial Infarction, andhe first randomized trial comparing abciximab and eptifi-
atide as adjuncts to primary PCI in patients with acute
TEMI. By far the best studied GP IIb/IIIa inhibitor in
atients with primary PCI is abciximab. In a meta-analysis,
t was shown to reduce death and myocardial infarction (9).
n the most recent trial of abciximab versus placebo in
atients undergoing primary PCI, STR was significantly
mproved with abciximab, indicating improved myocardial
eperfusion, and this advantage was associated with reduced
ortality after 12 months (8).
There are no randomized controlled trials available com-
aring eptifibatide with placebo in patients undergoing
rimary PCI for acute STEMI. Similar to abciximab,
ptifibatide inhibits platelet aggregation through GP IIb/
IIa receptor blockade. In contrast to abciximab, eptifibatide
nduces a competitive and rapidly reversible antagonism,
hich might be desirable in patients with bleeding events or
he need for urgent coronary bypass grafting. However, the
ffect of abciximab can be readily reversed by platelet
ransfusions, which might not have the same efficacy in
afety Events Until Day 30Table 6 Safety Events Until Day 30
Variable
Eptifibatide
(n  226)
Abciximab
(n  201) p Value
TIMI major bleeding 9 (4.0%) 4 (2.0%) 0.27
TIMI minor bleeding 28 (12.4%) 18 (9.0%) 0.28
Stroke 1 (0.4%) 1 (0.5%) 1.00
Moderate thrombocytopenia (in hospital)
100,000 cells/mm3
5 (2.2%) 7 (3.5%) 0.56
Severe thrombocytopenia (in hospital)
50,000 cells/mm3
1 (0.4%) 0 1.00
IMI  Thrombolysis In Myocardial Infarction.Urgent Target Vessel Revascularization Until Day 240
p
(
i
t
t
p
u
a
m
i
p
p
a
p
6
n
i
f
b
l
t
h
a
e
a
t
e
r
t
m
r
w
S
b
a
h
i
p
i
b
a
a
i
t
e
r
C
O
P
t
R
H
w
R
1
1
1
1
1
1
1
1
1
1
2
468 Zeymer et al. JACC Vol. 56, No. 6, 2010
Eptifibatide Versus Abciximab in Primary PCI August 3, 2010:463–9atients treated with the small molecules. Kereiakes et al.
23) compared ex vivo platelet function at the time of PCI
n patients with unstable angina who were treated with 1 of
he 3 GP IIb/IIIa antagonists eptifibatide, abciximab, or
irofiban. In this study, the consistency of the level of
latelet inhibition with abciximab was more diverse and less
niform compared with that with eptifibatide. Platelet
ctivation in patients with STEMI and primary PCI is
uch higher than in those with elective PCI, so a random-
zed trial is necessary to compare these 2 compounds in
rimary PCI. Our study was powered on the basis of the
reservation of a difference of at least 25% in the effect of
bciximab on the recovery of ST-segment deviation versus
lacebo. From previous experience, we estimated a rate of
0% complete STR in the abciximab group. This aim was
early achieved with a complete STR rate of 56.3% in the
ntention-to-treat analysis. We observed no significant dif-
erence in complete STR between abciximab and eptifi-
atide, and the criteria for noninferiority were met. The
ower 95% confidence interval indicated that at least 75% of
he benefit of abciximab over placebo was preserved. STR
as been shown to be closely related to myocardial perfusion
nd mortality in STEMI (20,21,24,25), so this is an
xcellent surrogate end point for comparative trials (26,27)
nd has been widely used.
Our study was not powered to detect any differences in
he rate of clinical events. However the rate of the combined
nd point of death, nonfatal reinfarction, and target vessel
evascularization was identical after 6 months. Although
here were fewer reinfarctions with eptifibatide, we observed
ore major bleeding complications with eptifibatide. The
eason might be the different durations of the infusions,
hich were 14 h with abciximab and 22 h with eptifibatide.
tudy limitations. This was an open study, leaving some
ias for the investigators. However, the STR end points and
ngiographic evaluations were done centrally by blinded and
ighly experienced core laboratories.
Our results are confirmed by a nonrandomized compar-
son of abciximab and eptifibatide in patients undergoing
rimary PCI (19). In the propensity score analysis, the
nvestigators found no difference in hospital mortality or
leeding complications. In 2 recent randomized trials, an
ccelerated infusion regimen of tirofiban was as effective and
s safe as abciximab in primary PCI (26,27), suggesting that
f the small molecule GP IIb/IIIa inhibitors eptifibatide and
irofiban are given in dose regimens ensuring a rapid and
ffective initial platelet inhibition their effects seem compa-
able with those of the gold standard abciximab.
onclusions
ur results suggest that eptifibatide as an adjunct to primary
CI in STEMI is equally effective to abciximab with respecto complete STR, a measure of myocardial reperfusion.eprint requests and correspondence: Prof. Dr. Uwe Zeymer,
erzzentrum Ludwigshafen, Bremserstrasse 79, D-67063 Lud-
igshafen, Germany. E-mail: uwe.zeymer@t-online.de.
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